Changjie Lou

Harbin, 150081, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Electroacupuncture combined with fruquintinib and sintilimab in microsatellite-stable metastatic colorectal cancer: A phase II study.

Electroacupuncture combined with fruquintinib and sintilimab in microsatellite-stable metastatic colorectal cancer: A phase II study.

Journal: Cancer letters

Published: November 18, 2025

Mechanical force regulates the inhibitory function of PD-1.

Mechanical force regulates the inhibitory function of PD-1.

Journal: EMBO reports

Published: February 11, 2025

Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma.

Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma.

Journal: Clinical and experimental medicine

Published: November 30, 2024

TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism.

TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 25, 2024

Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.

Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.

Journal: The oncologist

Published: January 18, 2024

PD-1 Inhibitors Combined with Tyrosine Kinase Inhibitors with or without Hepatic Artery Infusion Chemotherapy for the First-Line Treatment of HBV-Related Advanced Hepatocellular Carcinoma: A Retrospective Study.

PD-1 Inhibitors Combined with Tyrosine Kinase Inhibitors with or without Hepatic Artery Infusion Chemotherapy for the First-Line Treatment of HBV-Related Advanced Hepatocellular Carcinoma: A Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: January 02, 2024

Self-programmed dynamics of T cell receptor condensation.

Self-programmed dynamics of T cell receptor condensation.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 03, 2023

Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.

Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.

Journal: Cancer immunology, immunotherapy : CII

Published: June 27, 2023

Recent advances in natural polysaccharides against hepatocellular carcinoma: A review.

Recent advances in natural polysaccharides against hepatocellular carcinoma: A review.

Journal: International journal of biological macromolecules

Published: May 28, 2023

Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.

Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.

Journal: Therapeutic advances in medical oncology

Published: September 13, 2022

Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.

Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.

Journal: BMC cancer

Published: August 05, 2022

Preoperative peripheral blood inflammatory markers especially the fibrinogen-to-lymphocyte ratio and novel FLR-N score predict the prognosis of patients with early-stage resectable extrahepatic cholangiocarcinoma.

Preoperative peripheral blood inflammatory markers especially the fibrinogen-to-lymphocyte ratio and novel FLR-N score predict the prognosis of patients with early-stage resectable extrahepatic cholangiocarcinoma.

Journal: Frontiers in oncology

Published: July 26, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026